Chemical Structure Of Nilotinib (Tasigna 01)
Tasigna Capsule
Product Images NDC 0078-0592
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tasigna (NDC 0078-0592). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 14-1 Kaplan-meier Estimate Of Treatment-free Survival After Start Of Tfr (full Analysis Set Enestfreedom) (Tasigna 02)
Figure 14-2 Kaplan-meier Estimate Of Treatment-free Survival After Start Of Tfr (full Analysis Set Enestop) (Tasigna 03)
The text appears to be a chart representing Treatment free survival over time, with percentage values indicated in the leftmost column and time since TFR (in weeks) in the top row. The chart also includes some additional text and symbols that are not clearly readable.*
Ndc 0078-0592-87tasigna(nilotinib) Capsules150 mg (Tasigna 04)
Ndc 0078-0526-87tasigna(nilotinib) Capsules200 mg (Tasigna 05)
This is a medical description of Tasigna (nilotinib) capsules, containing 200mg per capsule. The drug is for oral use and comes in a blister pack of 28 capsules. The recommended storage temperature is between 20°C to 25°C, and the medication guide should be attached or provided separately. For more information, visit the USTASIGNA website or consult the prescribing information.*
Ndc 0078-0951-8766tasigna(nilotinib) Capsules50 mg (Tasigna 06)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
